METABOLISM OF AFLATOXIN AND OTHER MYCOTOXINS IN RELATION TO THEIR TOXICITY
AND THE ACCUMULATION OF RESIDUES IN ANIMAL TISSUES

D. S. P. Patterson
Central Veterinary Laboratory, Weybridge, Surrey, England, KT15 3NB

Abstract — Mycotoxin metabolism is discussed in relation to
(1) detoxification, (2) metabolic activation and mode of action, and
(3) the public health problem arising from the possible accumulation of
toxic residues in the tissues of farm animals consuming toxin-
contaminated feeds. The aflatoxins, sterigmatocystin, ochratoxins A
and B, the trichothecenes, and zearalenone are considered as far as our
available knowledge permits. Mycotoxin metabolism may not only take
place in the liver; the skin and gastro-intestinal tract may be
alternative sites.

INTRODUCTION

In the paper for one of the poster sessions at this Symposium I have already referred to our
limited knowledge of mycotoxin metabolism (Ref. 1). Even in the case of aflatoxin the relation-
ship between metabolism and toxicity is still being explored and, by comparison, very
little is known of this aspect of the metabolism of the growing number of mycotoxins that
have now implicated in clinical or experimental animal disease.

Despite the somewhat limited information available in some cases, I shall briefly consider
the metabolism of the aflatoxins, sterigmatocystin, ochratoxins A and B, and the Fusarium
toxins with regard to their mode of action and their potential for accumulating as toxic
residues in animal tissues. Before doing this however, it may be useful to define a few
terms that I shall be using.

"Detoxification" will be taken to mean the biotransformation of a toxin, usually by the
microsomal mixed function oxidases of the liver, to a metabolite that is either non-toxic
when ingested by a second animal of the same or different species, or a metabolite that
results from the conjugation of the toxin with cysteine, glutathione, or glucuronic, tauro-
cholic or sulphuric acids in a further microsomal reaction to form more polar compounds that
are rapidly eliminated from the body by excretion into the urine or bile for example.

A mycotoxin will be said to have the potential for accumulating "toxic residues" in body
tissues when its metabolism in vitro or better still in vivo is known to be slow or,
alternatively, when a significant pathway of metabolism results in the formation of one or
more metabolites with no appreciable loss in toxicity and when such a product is slowly
eliminated from the body. This potential problem is greatest when the animal in question is
destined for use as human food.

"Metabolic Activation" differs from the above in that it involves biotransformation of the
mycotoxin in question to at least one metabolite which, unlike the toxic metabolites just
mentioned, is more toxic than the parent toxin and also plays a key role in the mechanism of
toxic action in the appropriate target organ.

Clearly the precise outcome of these possible metabolic processes or biotransformations will
depend upon their relative importance in a given animal species but, by definition, none of
the toxins in question are detoxified so well that animals are entirely unaffected by toxin
ingestion. In certain animal species however these "detoxifying" pathways appear to be
better developed than in others. Metabolic activation, on the other hand, is a property not
common to all mycotoxins and appears to be reserved for the most potent ones. Perhaps we can
regard this as similar to the type of reaction which, in an entirely different context, Sir Rudolph Peters referred to as "lethal synthesis".

These generalised aspects of mycotoxin metabolism are summarised in Fig. 1 and the metabolism
of some individual mycotoxins will now be considered in this general format but not in great
detail so as to provide an overview of as many toxins as possible.
**Fig. 1.** A generalised scheme showing typical pathways of mycotoxin metabolism in the liver resulting in detoxification, the accumulation of toxic residues in tissues, and metabolic activation.

**Fig. 2.** Pathways for the metabolism of aflatoxin B₁ in the liver. The 2,3 dihydro analogue (aflatoxin B₂) is metabolised by reactions m₁, m₄, m₅ and c₁ and apart from c₁ and m₅ the G series of aflatoxins may be metabolised through the same pathways. GS denotes glutathione.
AFLATOXIN

As summarized in Fig. 2 aflatoxin B₁ metabolism may be considered under all three of the above headings.

Detoxification. Aflatoxin B₁ may be transformed in the liver into three hydroxylated metabolites (aflatoxicol, aflatoxin Q₁ and aflatoxin P₁) that are at least theoretically capable of conjugation to polar compounds suitable for rapid elimination from the body. To this extent these reactions involve detoxification and when tested in various in vivo systems for acute toxicity they are all appreciably less toxic than the parent toxin (see review, Ref. 2).

Aflatoxicol occupies a special position in that it is not formed in a microsomal mixed function oxidase reaction but by an NADP-linked dehydrogenase of the cytosol which also has 17-ketosteroid dehydrogenase activity. Further more this reaction is reversible to a greater or lesser extent and it has been proposed (Ref. 3 and 4) that this reversible reaction constitutes a "metabolic reservoir" of aflatoxin. Recently this suggestion has been developed further by Hsieh (Ref. 5) to provide a good correlation between this type of metabolism and an animal's susceptibility to aflatoxin poisoning.

It will also be noted from Fig. 2 that the same enzymic reduction of the cyclopentenone carbonyl group occurs in the case of aflatoxin Q₁ and probably this reaction is reversible.

Toxic residues. Aflatoxin is metabolised more rapidly by some animal species than others (Ref. 4) and consequently in "slow metabolising" animals (see classification in Ref. 4 and 6) aflatoxin B₁ can itself constitute a residue problem particularly in tissues of farm animals. Biotransformation to aflatoxin M₁ by microsomal enzymes (Fig. 2) is to some extent a detoxification since conjugates of this metabolite have been identified in bile (Ref. 7) and urine (Ref. 8) but because unconjugated M₁ is almost as toxic as B₁ it must still be regarded as a potential toxic residue. As is well known, a considerable public health problem exists in the excretion of aflatoxin M₁ in the milk of dairy cows consuming rations contaminated with aflatoxin.

Metabolic activation is dependent upon the existence of a 2,3-vinyl ether double bond in the aflatoxin B₁ molecule (and possibly any aflatoxin derivative carrying this chemical function). The two proposals for metabolic activation are illustrated in Fig. 2 and more detail of the interactions by the activated forms of aflatoxin B₁ with cellular structures and constituents are given in Fig. 3.

The first proposal made in our laboratory (Ref. 9 and 10) was that, as the metabolic conversion of aflatoxin B₁ to its hemiacetal, B₂ₐ appeared to be characteristic of livers of animal species susceptible to acute aflatoxin poisoning, it was in this form that it interacted with vital functions of the liver cell leading to hepatocellular necrosis. At physiological and alkaline pH values it was known that aflatoxin hemiacetal rearranges to dialdehydic phenolate resonance hybrid ions (Ref. 11) and in this form it reacted with amino acids, peptides and proteins to form Schiff bases (see Fig. 3). An important distinction was made between metabolic formation and toxicity of this product within the hepatocyte and the known lack of oral toxicity of aflatoxin hemiacetal in vivo. The latter we felt, could be explained by its avid protein binding capacity and thus its sequestration by the decidual cells of the gastrointestinal tract. In this way it would effectively escape significant absorption. Thus, intra-hepatocellular formation of the hemiacetal was the central feature of this hypothesis but equal emphasis has always been placed on the fact that this biotransformation is best developed in the normal livers of animal species with a high susceptibility to acute aflatoxin poisoning.

The second proposal originated by Garner and his colleagues (Ref. 12 and 13) was that livers of most, if not all, animal species are capable of converting aflatoxin B₁ to an unidentified toxic metabolite which could be assayed in a bacterial mutagenicity test. It was suggested that this metabolic product was the 2,3-oxide, that it had a transient existence and that it alkylated bacterial DNA. So far there is no direct evidence for the 2,3-oxide but it has been shown (Ref. 14) that when aflatoxin B₁ was incubated in vitro with liver microsomes and RNA or DNA, a nucleic acid adduct was formed which, on mild hydrolysis, yielded the 2,3-dihydrodiol of aflatoxin, indirectly suggesting prior formation of the 2,3-oxide. Further studies by Swenson and his colleagues (Ref. 15) have shown that synthetic aflatoxin 2,3-dichloride can mimic the biological effects of this presumed metabolite in all the appropriate bioassay systems.

Thus we have two distinct hypotheses. First, that aflatoxin B₁ may be activated by a metabolic conversion to hemiacetal which binds to various key enzymes and metabolically important liver cell structures. This we might call formation of the acute toxin. Second, that the toxin is activated to the hypothetical 2,3-oxide and because it is mutagenic it is also presumed to be the proximal carcino-ogen. Any 2,3-oxide unreacted with DNA might be hydrated enzymically in the liver to form the dihydrodiol of aflatoxin which would have
Fig. 3. Special aspects of aflatoxin B₁ metabolism (partial structures only) showing two routes for metabolic activation to the hemiacetal (B₂a) and the 2,3 oxide (epoxide). Interactions of these metabolites with protein and DNA and inactivation of the epoxide by enzymic reaction with glutathione are also indicated (see Ref. 4, 10 and 15).

**ACTIVATED FORMS**

**TOXIC RESIDUES**

**DETOXIFICATION**

Probable microsomal pathways (m₁,₃)

Fig. 4. Sterigmatocystin metabolism in the liver probably follows the pathways shown. There appears to be only one form of metabolic activation. GS denotes glutathione.
somewhat similar properties to the hemiacetal, binding with amino acids etc. to form Schiff bases (Fig. 3). Conjugation with glutathione (GSH) might provide an alternative detoxification of the epoxide (Ref. 16).

**STERIGMATOCYSTIN**

Again this toxin can be considered under all three headings.

**Detoxification.** Relatively little is known of the metabolism of this toxin. At least two microsomal reactions are possible in the liver (demethylation and conjugation) and as glucurononides of sterigmatocystin have been identified in the urine of treated Vervet monkeys (Ref. 17) these two reactions are depicted in the Fig. 4. As in the case of aflatoxin, these reactions would be detoxifications only in the sense that more polar and more readily excreted forms of the toxin are produced.

**Toxic residues.** Little is known of the relative rates of sterigmatocystin metabolism by livers of different animal species, but clearly those metabolising it slowly are likely to accumulate this carcinogenic toxin in their tissues. By analogy with aflatoxin it is also possible that a 4-hydroxy compound is formed metabolically and if so this would presumably be toxic as the 2,3-vinyl ether grouping is generally assumed to be the active centre of the sterigmatocystin molecule.

**Metabolic activation.** Liver preparations which form the hemiacetal of the aflatoxin in vitro fail to carry out the equivalent transformation when sterigmatocystin is used as substrate (Ref. 9). Therefore this type of metabolic activation would seem to be unlikely. However, using the bacterial mutagenicity test, Garner and his colleagues (Ref. 12 and 13) have shown that the presumed 2,3-oxide is probably formed by liver microsomes (see Fig. 4).

**OCHRATOXIN A**

No active forms of this toxin are known so it can be discussed under two headings only.

**Detoxification.** The only metabolic reaction of ochratoxin A results in detoxification. Hydrolysis catalysed by carboxypeptidase A breaks the amide bond (Ref. 18) with the formation of the naturally occurring amino acid phenylalanine plus ochratoxin a (Fig. 5). The latter isocoumarin carboxylic acid is very much less toxic than the parent toxin ochratoxin A in all acute in vivo and in vitro test systems (e.g. Ref. 19) and thus the complete toxin molecule appears to be required to achieve its toxic effect.

**Toxic residues.** Its precise mode of action and the reasons for its peculiar affinity for the proximal tubules of the kidney remain unknown but ochratoxin A binds strongly to protein and the affinity constant is higher for this toxin than the dechloro-derivative ochratoxin B (Ref. 20). As a protein binding agent ochratoxin A clearly presents a toxic residue problem. Pigs exposed to this toxin in their diet accumulate ochratoxin A in kidney, liver and muscle (in decreasing order) and the experimental regression equations of Krogh and his colleagues (Ref. 21) have been found by other experimenters (Ref. 22) to provide a fairly good means of predicting levels of these toxic residues.

**TRICHOCOCYCINES**

This group comprises over 30 toxins elaborated by Fusarium, Trichothecium, and Stachybotrys spp. for example and none appears to be metabolically activated. Their dermal toxic action on the skin demonstrates that at least in this particular mode of action this is the case. Therefore these mycotoxins will also be considered under two headings only.

**Detoxification.** Assuming that the epoxide group is the "active centre" of the typical trichothecene molecule it is obvious that modifications of acyl or ester groups R₂, R₃, and R₄ (see Fig. 6) will only have modifying effects on toxicity. Thus there is evidence (Ref. 23) to show that T-2 toxin (R₂ = β-acetoxy; R₃ = acetoxy; R₄ = α-hydroxy; R₅ = α-isovaleroyx) is hydrolysed by liver tissues in vitro to the HT-2 toxin (R₁ = β-hydroxy) and like T-2 toxin itself it is still reactive in the dermal toxicity test. Only chemical modification of the epoxide will result in detoxification (see Fig. 6) although hydroxylated trichothecene mycotoxins are probably excreted as glucuronides (Ref. 24).

Chemical reduction with lithium aluminium hydride has been shown to destroy the toxic action of trichothecene toxins (Ref. 25) and so reduction in the liver or other tissues would be a detoxifying reaction. Enzymic modification with microsomal epoxide hydrolase or the soluble glutathione S-epoxide transferase are obvious alternatives and it has been shown that crude liver homogenates containing both these enzymes do indeed destroy the toxic properties of T-2 toxin (Ref. 24), scirpene triacetate and diacetoxydircpenol (Ref. 9 and 26).
Fig. 5. Ochratoxin A is enzymically hydrolysed to phenylalanine and biologically inactive ochratoxin α mainly in the intestine but also in the liver.

Fig. 6. Three possible pathways for the metabolism of 12,13-epoxy- Δ^9-trichothecone mycotoxins. In the generalised structure of these toxins given above R_1, R_2, R_3 and R_4 may be hydrogen, hydroxyl, esterified hydroxyl, keto (R_4 only), epoxide (replaces R_4 and adjacent OH group), or a macrocyclic bridge may link R_1 and the adjacent CH_2 group. The OH group adjacent to R_4 is replaced by hydrogen in some toxin molecules.
Ring rearrangement (Fig. 6) occurs under strongly acid conditions but our own unpublished experiments have shown that in the milder acidic conditions of the stomach this rearrangement is extremely unlikely.

**Toxic residues.** Nothing is known of in vitro stability or rates of metabolism of this group of toxins in different animal species but it has been shown that binding to sulphydryl groups of cysteine, glutathione and protein molecules occurs (Ref. 27). This may prove to be an essential part of the mode of action of these toxins but equally it may denote a potential residue problem when domestic animals have been exposed to trichothecene contaminated feeds.

**ZEARALENONE**

Another Fusarium toxin, the toxicology of zearalenone has received much attention but rather little is known of its metabolism and mode of action.

**Detoxification.** No pathways have yet been defined but at least two of the possible metabolites of zearalenone contain hydroxyl groups and presumably conjugates such as glucuronides could be formed by microsomal glucuronyl transferases (see Fig. 7).

**Toxic residues.** Again no information is available to identify animal species that metabolise zearalenone slowly but such a farm animal could possibly store toxic residues of the unchanged toxin with attendant health risks to the human consumer. Several metabolites of zearalenone are known to be formed by NAD/NADP-linked dehydrogenases present in the liver cell sap (Ref. 28) and these soluble enzymes probably convert the parent toxin into three oestrogenic compounds. If, as seems likely, reduction of the 3'-carbonyl group is essential for oestrogenic activity, perhaps this occurs at the site of action.

Zearalenol (or zeranol, Ralgro\(^\text{R}\)) is a widely approved anabolic preparation used for fattening cattle from which it is obvious that residues of this compound present very much less of a public health problem than diethylstilboestrol for example. Therefore it is probable that metabolites of zearalenone present only theoretical hazards as toxic residues, possibly in adipose tissues of animals that metabolise this toxin slowly.

**Activated form.** This has been discussed above in relation to general metabolism of this toxin.

**OESTROGENIC TOXINS AND PSEUDO--STEROIDS**

Zearalenone and its reduction products are uterotrophic like oestradiol 17\(\beta\) and, although these toxin molecules are not steroids, their oestrogenic activity must depend upon steroid-like interaction with appropriate receptor sites. This may involve pairs of hydroxyl or potential hydroxyl groups. Thus, as shown in Fig. 8, the macrocyclic zearalenone molecule could easily fold so that spacing of reactive groups \(a\) is equal to \(b\). Aflatoxin also behaves as a pseudo-steroid in that it can occupy oestradiol-binding sites of the liver endoplasmic reticulum (Ref. 29) as well as active sites of liver 17-ketosteroid dehydrogenase (Ref. 30). These interactions may be explained in similar terms because measurements from molecular models show that the spacing of the potential phenolic hydroxyl and the enzymically reducible carbonyl group of aflatoxin is approximately equal to that of the two hydroxyls in oestradiol (\(b\) and \(c\) in Fig. 8).

**EXTRA--HEPATIC METABOLIC ACTIVATION**

Finally, on both sides of the Atlantic we have, for the past few years, devoted much time and effort to examining the metabolism of mycotoxins in the liver. However this should not be regarded as the sole site of in vivo biotransformation. For example, Newberne and his research group (Ref. 31) have shown that aflatoxin may be activated in the skin and our own preliminary observations (Ref. 32) suggest that, possibly, the hemiacetal is formed in a free radical type reaction under the influence of ultra violet radiation. The former group (Ref. 33) have now shown that irradiated rats are less likely than unirradiated aflatoxin-dosed rats to develop hepatomas. Could this possibly be because an upset in the balance of aflatoxin metabolism—more hemiacetal and less epoxide formed?

And then, what of the stomach and gastrointestinal tract? The acid conditions themselves, the action of digestive enzymes, and the gut flora are factors that have simply not been given sufficient attention. In the case of ruminants and other herbivores, microbial biotransformations surely cannot be without importance.
Fig. 7. Zearalenone (F2) metabolism in the liver may follow the pathways shown.

Fig. 8. A possible molecular basis for the pseudo-steroid activities of aflatoxin and zearalenone. Hydroxyl or potential hydroxyl groups of these toxin molecules and oestradiol 17β may be identically spaced (a = b = c) when interacting with common receptor sites.
Metabolism of aflatoxin and other mycotoxins

REFERENCES
